Eli Lilly and Company
LLY.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.45T
Close$
Share Statistics
| Market cap | $1.45 Trillion |
|---|---|
| Enterprise Value | $1.50 Trillion |
| Dividend Yield | $5.74 (0.57%) |
| Earnings per Share | $23.01 |
| Beta | 0.5 |
| Outstanding Shares | 892,400,000 |
Return
| Return on Equity | 78.84% |
|---|---|
| Return on Assets | 18.77% |
| Return on Invested Capital | 35.50% |
Valuation & Multiples
| P/E Ratio | 39.45 |
|---|---|
| PEG | 155.68 |
| Price to Sales | 11.74 |
| Price to Book Ratio | 28.24 |
| Enterprise Value to Revenue | 18.86 |
| Enterprise Value to EBIT | 44.75 |
| Enterprise Value to Net Income | 56 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 1.78 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$5.60
Average shareholder expectationRevenue Estimate
$18.23 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$8.76
Average shareholder expectationRevenue Estimate
$19.68 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lilly(Eli) & Co
50,000 employees
CEO: David Ricks Eli Lilly and Company operates internationally as a pharmaceutical enterprise, dedicated to the discovery, development, and commercialization of human therapeutics. Its comprehensive product lineup addresses numerous critical health area...